UroGen Pharma Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of UroGen Pharma Ltd. generated cash of -$76,376,000, which is more than the previous year. Cash used in financing activities reached the amount of $116,931,000 last year. Net change in cash is therefore $39,602,000.
Cash Flow
| 2015 | -7.17M | -301K | 21.58M |
|---|---|---|---|
| 2016 | 4.18M | -793K | -9K |
| 2017 | -9.57M | -36.37M | 61.58M |
| 2018 | -37.33M | 35.28M | 66.42M |
| 2019 | -71.01M | -145.59M | 165.25M |
| 2020 | -105.88M | 93.23M | 16.52M |
| 2021 | -84.89M | 4.06M | 72.31M |
| 2022 | -87.55M | 1.06M | 97.13M |
| 2023 | -76.37M | -953K | 116.93M |
URGN Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 56.22M | 45.58M | 54.09M | 50.21M | 101.57M | 37.19M | 21.36M | 17.97M | 3.87M |
Operating activities | |||||||||
Net income | -102.24M | -109.78M | -110.82M | -128.48M | -105.14M | -75.65M | -20M | -1.94M | -12.68M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 1.70M | 1.81M | 1.77M | 2.04M | 1.32M | 417K | 207K | 213K | 113K |
Stock-based compensation expense | 9.34M | 10.58M | 23.11M | 28.02M | 29.96M | 0 | 6.3M | 1.96M | 449K |
| Deferred income tax benefit | 9.34M | 10.58M | 23.11M | 28.02M | 29.96M | 0 | 6.3M | 1.96M | 449K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -2.73M | -987K | -4.67M | -7.04M | 0 | 3.29M | 83K | -83K | 0 |
Inventories | -1.34M | -362K | -2.86M | -1.96M | 0 | 316K | -211K | -105K | 0 |
Accounts payable | 4.15M | 281K | 1.99M | -1.24M | 2.92M | 4.20M | 2.53M | 481K | 1.15M |
Cash generated by operating activities | -76.37M | -87.55M | -84.89M | -105.88M | -71.01M | -37.33M | -9.57M | 4.18M | -7.17M |
Investing activities | |||||||||
Purchases Of Investments | -49.83M | -63.00M | -51.89M | -29.68M | -197.68M | 0 | -36.00M | 0 | 0 |
Investments In Property Plant And Equipment | -194K | -254K | -752K | -1.21M | -325K | -560K | -271K | -695K | -301K |
Acquisitions Net | 0 | -1.31M | -4.82M | -94.45M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -953K | 1.06M | 4.06M | 93.23M | -145.59M | 35.28M | -36.37M | -793K | -301K |
Financing activities | |||||||||
Common Stock Issued | 67.35M | 1.35M | -83K | 15.85M | 161.66M | 64.23M | 60.84M | 0 | 21.58M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 95.78M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 116.93M | 97.13M | 72.31M | 16.52M | 165.25M | 66.42M | 61.58M | -9K | 21.58M |
Net Change In Cash | 39.60M | 10.63M | -8.50M | 3.87M | -51.36M | 64.37M | 15.63M | 3.38M | 14.10M |
Cash at end of period | 95.82M | 56.22M | 45.58M | 54.09M | 50.21M | 101.57M | 36.99M | 21.36M | 17.97M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |